STERIS plc (NYSE:STE) Shares Acquired by Blue Zone Wealth Advisors LLC

Blue Zone Wealth Advisors LLC raised its holdings in shares of STERIS plc (NYSE:STE) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,788 shares of the medical equipment provider’s stock after acquiring an additional 520 shares during the period. STERIS makes up about 1.5% of Blue Zone Wealth Advisors LLC’s portfolio, making the stock its 24th biggest position. Blue Zone Wealth Advisors LLC’s holdings in STERIS were worth $5,301,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in shares of STERIS by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 2,303,625 shares of the medical equipment provider’s stock valued at $556,786,000 after purchasing an additional 17,007 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of STERIS by 9.5% during the 3rd quarter. Principal Financial Group Inc. now owns 1,114,224 shares of the medical equipment provider’s stock valued at $270,230,000 after purchasing an additional 96,336 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of STERIS by 171.2% during the 3rd quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock valued at $191,370,000 after purchasing an additional 529,308 shares in the last quarter. Raymond James & Associates increased its holdings in shares of STERIS by 1.5% during the 3rd quarter. Raymond James & Associates now owns 801,144 shares of the medical equipment provider’s stock valued at $194,309,000 after purchasing an additional 12,005 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of STERIS by 1.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 551,453 shares of the medical equipment provider’s stock valued at $133,749,000 after purchasing an additional 6,334 shares in the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

STERIS Trading Up 0.1 %

Shares of STE opened at $219.54 on Friday. STERIS plc has a 52-week low of $197.82 and a 52-week high of $248.24. The company has a quick ratio of 1.55, a current ratio of 2.13 and a debt-to-equity ratio of 0.32. The firm’s fifty day moving average is $212.95 and its two-hundred day moving average is $224.09. The stock has a market cap of $21.67 billion, a PE ratio of 46.61 and a beta of 0.84.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. Research analysts forecast that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $2.28 annualized dividend and a yield of 1.04%. STERIS’s dividend payout ratio (DPR) is presently 48.41%.

Analyst Ratings Changes

STE has been the subject of several recent research reports. JMP Securities reaffirmed a “market outperform” rating and set a $265.00 target price on shares of STERIS in a report on Thursday, February 6th. Stephens reissued an “overweight” rating and issued a $240.00 price target on shares of STERIS in a report on Thursday, February 6th. StockNews.com lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Piper Sandler boosted their price target on shares of STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of STERIS in a report on Friday, November 8th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $258.75.

Insiders Place Their Bets

In other news, SVP Cary L. Majors sold 1,682 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the transaction, the senior vice president now owns 11,372 shares of the company’s stock, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.14% of the stock is currently owned by corporate insiders.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.